Results 201 to 210 of about 127,271 (293)

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Congestive Heart Failure as Initial Manifestation of Biventricular Arrhythmogenic Cardiomyopathy With MYBPC3 and DSG2 Variants. [PDF]

JACC Case Rep
Alanís-Naranjo JM, Patrón-Chi SA, Campuzano-González D, Cruz-Marmolejo MÁ, De la Cruz-Pelayo J, Meléndez-Ramírez G, Meave-González A.   +6 more
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Effect of scar distribution on transmural and planar repolarization gradients and dispersion in non-ischemic cardiomyopathies with ventricular arrhythmias. [PDF]

Europace
Tonko JB, Cabrera-Borrego E, Sánchez-Millán P, Jiménez-Jáimez J, Chow A, Lambiase PD.   +5 more
europepmc   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source

Exercise Rehabilitation for Heart Failure and Associated Cardiomyopathies. [PDF]

Curr Cardiol Rep
Stahl ME, Weeldreyer NR, MacNamara JP, Lozano PFR, Allen JD.   +4 more
europepmc   +1 more source

Prenatal betamethasone–postnatal N‐methyl‐D‐aspartic acid model of spasms: Update on mechanisms and treatments

Epilepsia Open, EarlyView.
Abstract Infantile epilepsy spasms syndrome (IESS), formerly known as infantile spasms or West Syndrome, is a severe epilepsy syndrome affecting about 3 in 10,000 newborns in the United States. Characterized by clusters of epileptic spasms, interictal hypsarrhythmia, and developmental delays, IESS has diverse causes, including structural‐metabolic ...
Kayla Vieira, Antonia Schonwald, Chian‐Ru Chern, Kamya Shah, Jana Velíšková, Libor Velíšek   +5 more
wiley   +1 more source

Between hope and hype: assessing artificial intelligence in cardiovascular imaging. [PDF]

Eur Heart J Imaging Methods Pract
Fortuni F, Ciliberti G, Ricci F, Emanuele F, Carluccio E, Moreo A.   +5 more
europepmc   +1 more source

A Rare Occurrence of Dilated Cardiomyopathy and Long Qt Syndrome in a Child with Graves’ Disease: A Case Report and Review of Literature

Siti Salamah Mohd Idris, Shabneez Hussain, Anis Munirah Mohd Kori   +2 more
openalex   +2 more sources

Ketogenic diet for infantile epileptic spasms

Epilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury, Anamika Choudhary, Andy Cheuk‐Him Ng, Cezar Gavrilovici   +3 more
wiley   +1 more source